Healthcare
RepliCel Life Sciences Inc.(REPCF)
Live Price
Offline$0.0001
+0.00% today
1Y Change
-95.00%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- -0.1%
- EPS Growth
- -262.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RepliCel Life Sciences Inc. (REPCF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 95.0% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -0.1%, EPS growth of -262.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.1%, EPS -262.5%, free cash flow +44.2% with operating margin -101.8% and ROIC 49.9%. Valuation is more restrained than many high-expectation growth names at price/sales 3.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines REPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.1% vs +7.6% peer median
Operating Margin
Below sector median
-101.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Aug 4, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.1% and EPS is at -262.5%, with operating margin around -101.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Aug 4, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 19, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Mar 31, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REPCF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
REPCF Max Drawdown
-99.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for REPCF and SPY.
Company Overview
RepliCel Life Sciences Inc.
Other OTC
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
- Leadership
- Andrew Schutte
- IPO Date
- May 3, 2010
- Employees
- 1
- Street Address
- 570 Granville Street
- Mailing
- Vancouver, BC, V6C 3P1
- Region
- Vancouver, BC, CA
- Reporting Currency
- USD
- Investor Line
- 604 248 8730
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.1
- Price/Book
- โ
Growth
- Revenue
- -0.1%
- EPS
- -262.5%
- Free Cash Flow
- +44.2%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -101.8%
- Net Margin
- -27.5%
- ROE
- 1.9%
- ROIC
- 49.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.